247 related articles for article (PubMed ID: 25305204)
1. The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV.
Murai MJ; Pollock J; He S; Miao H; Purohit T; Yokom A; Hess JL; Muntean AG; Grembecka J; Cierpicki T
Blood; 2014 Dec; 124(25):3730-7. PubMed ID: 25305204
[TBL] [Abstract][Full Text] [Related]
2. Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia.
Cermáková K; Tesina P; Demeulemeester J; El Ashkar S; Méreau H; Schwaller J; Rezáčová P; Veverka V; De Rijck J
Cancer Res; 2014 Sep; 74(18):5139-51. PubMed ID: 25082813
[TBL] [Abstract][Full Text] [Related]
3. Menin critically links MLL proteins with LEDGF on cancer-associated target genes.
Yokoyama A; Cleary ML
Cancer Cell; 2008 Jul; 14(1):36-46. PubMed ID: 18598942
[TBL] [Abstract][Full Text] [Related]
4. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
[TBL] [Abstract][Full Text] [Related]
5. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription.
Huang J; Gurung B; Wan B; Matkar S; Veniaminova NA; Wan K; Merchant JL; Hua X; Lei M
Nature; 2012 Feb; 482(7386):542-6. PubMed ID: 22327296
[TBL] [Abstract][Full Text] [Related]
6. Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75).
Méreau H; De Rijck J; Cermáková K; Kutz A; Juge S; Demeulemeester J; Gijsbers R; Christ F; Debyser Z; Schwaller J
Leukemia; 2013 Jun; 27(6):1245-53. PubMed ID: 23318960
[TBL] [Abstract][Full Text] [Related]
7. Multiple cellular proteins interact with LEDGF/p75 through a conserved unstructured consensus motif.
Tesina P; Čermáková K; Hořejší M; Procházková K; Fábry M; Sharma S; Christ F; Demeulemeester J; Debyser Z; Rijck J; Veverka V; Řezáčová P
Nat Commun; 2015 Aug; 6():7968. PubMed ID: 26245978
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.
Grembecka J; Belcher AM; Hartley T; Cierpicki T
J Biol Chem; 2010 Dec; 285(52):40690-8. PubMed ID: 20961854
[TBL] [Abstract][Full Text] [Related]
9. Affinity switching of the LEDGF/p75 IBD interactome is governed by kinase-dependent phosphorylation.
Sharma S; Čermáková K; De Rijck J; Demeulemeester J; Fábry M; El Ashkar S; Van Belle S; Lepšík M; Tesina P; Duchoslav V; Novák P; Hubálek M; Srb P; Christ F; Řezáčová P; Hodges HC; Debyser Z; Veverka V
Proc Natl Acad Sci U S A; 2018 Jul; 115(30):E7053-E7062. PubMed ID: 29997176
[TBL] [Abstract][Full Text] [Related]
10. Unlike Its Paralog LEDGF/p75, HRP-2 Is Dispensable for MLL-R Leukemogenesis but Important for Leukemic Cell Survival.
Van Belle S; El Ashkar S; Čermáková K; Matthijssens F; Goossens S; Canella A; Hodges CH; Christ F; De Rijck J; Van Vlierberghe P; Veverka V; Debyser Z
Cells; 2021 Jan; 10(1):. PubMed ID: 33477970
[TBL] [Abstract][Full Text] [Related]
11. LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis.
El Ashkar S; Schwaller J; Pieters T; Goossens S; Demeulemeester J; Christ F; Van Belle S; Juge S; Boeckx N; Engelman A; Van Vlierberghe P; Debyser Z; De Rijck J
Blood; 2018 Jan; 131(1):95-107. PubMed ID: 29084774
[TBL] [Abstract][Full Text] [Related]
12. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
[TBL] [Abstract][Full Text] [Related]
13. Menin as a hub controlling mixed lineage leukemia.
Thiel AT; Huang J; Lei M; Hua X
Bioessays; 2012 Sep; 34(9):771-80. PubMed ID: 22829075
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
Borkin D; He S; Miao H; Kempinska K; Pollock J; Chase J; Purohit T; Malik B; Zhao T; Wang J; Wen B; Zong H; Jones M; Danet-Desnoyers G; Guzman ML; Talpaz M; Bixby DL; Sun D; Hess JL; Muntean AG; Maillard I; Cierpicki T; Grembecka J
Cancer Cell; 2015 Apr; 27(4):589-602. PubMed ID: 25817203
[TBL] [Abstract][Full Text] [Related]
15. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
[TBL] [Abstract][Full Text] [Related]
16. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.
Grembecka J; He S; Shi A; Purohit T; Muntean AG; Sorenson RJ; Showalter HD; Murai MJ; Belcher AM; Hartley T; Hess JL; Cierpicki T
Nat Chem Biol; 2012 Jan; 8(3):277-84. PubMed ID: 22286128
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein.
Murai MJ; Chruszcz M; Reddy G; Grembecka J; Cierpicki T
J Biol Chem; 2011 Sep; 286(36):31742-8. PubMed ID: 21757704
[TBL] [Abstract][Full Text] [Related]
18. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
[TBL] [Abstract][Full Text] [Related]
19. Protein-protein and protein-chromatin interactions of LEDGF/p75 as novel drug targets.
Blokken J; De Rijck J; Christ F; Debyser Z
Drug Discov Today Technol; 2017 Jun; 24():25-31. PubMed ID: 29233296
[TBL] [Abstract][Full Text] [Related]
20. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
